HSBC Holdings
ALXO icon

HSBC Holdings’s ALX Oncology ALXO Stock Holding History

HSBC Holdings’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.6K Hold
10,105
– – ﹤0.01% 2895
2026
Q1 		$20.5K Hold
10,105
– – ﹤0.01% 2857
2025
Q4 		$11.6K Sell
10,105
-712
-7% -$1.08K ﹤0.01% 2904
2025
Q3 		$19.1K Sell
10,817
-1,489
-12% -$1.29K ﹤0.01% 2674
2025
Q2 		$5.05K Sell
12,306
-3,822
-24% -$1.93K ﹤0.01% 3002
2025
Q1 		$9.66K Sell
16,128
-26
-0.2% -$31 ﹤0.01% 2987
2024
Q4 		$25.6K Buy
16,154
+2,235
+16% +$3.44K ﹤0.01% 3043
2024
Q3 		$25.7K Buy
13,919
+3,139
+29% +$11.7K ﹤0.01% 2931
2024
Q2 		$62.6K Buy
+10,780
New +$133K ﹤0.01% 2799
2024
Q1 		– Sell
-17,793
Closed -$263K – 3043
2023
Q4 		$263K Sell
17,793
-17,611
-50% -$167K ﹤0.01% 2344
2023
Q3 		$168K Buy
+35,404
New +$192K ﹤0.01% 2457

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

HSBC Holdings's ALXO Position: Q2 2026 in Review

HSBC Holdings held its ALX Oncology (ALXO) position steady in Q2 2026 at 10,105 shares worth $21.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2895.

HSBC Holdings first reported a position in ALXO in Q3 2023 and has held it in 11 quarters since. The position peaked at $263K in Q4 2023. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • HSBC Holdings held 10,105 shares of ALX Oncology worth $21.6K as of Q2 2026.
  • HSBC Holdings left its ALX Oncology share count unchanged in Q2 2026.
  • ALX Oncology made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2895 holding.
  • HSBC Holdings first reported a position in ALX Oncology in Q3 2023 and has held it in 11 quarters since.
  • HSBC Holdings's ALX Oncology position peaked at $263K in Q4 2023.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.